Symposium: Current management and emerging treatment in HBV

 Viral hepatitis
 Webcasted session

Main Plenary
14 April 2018 14:00 - 15:30

Hepatitis B virus (HBV) infection remains a major public health issue worldwide despite the availability of an effective vaccine and potent antiviral treatments that are able to suppress viral replication. Approximately one third of the world’s population has serological evidence of previous exposure to HBV, whereas 240 million people are chronic HBV surface antigen carriers who are at risk to develop advanced liver disease and Hepatocellular Cancer (HCC). 
This years HBV symposium will discuss some of the burning questions in Hepatitis B management:
Vaccination coverage and treatment opportunities are still unsatisfactory in highly endemic areas such as sub-Saharan Africa and parts of the Asia-Pacific region. In those areas of the world, anti-HBV strategies are fighting often with very limited resources, but there is some hope in some highly endemic countries due to improvements in the socioeconomic status, vaccination programs, and perhaps antiviral treatments.
In respect to antiviral treatment, HBsAg loss remains the highest goal but is only reached in a very small numbers of patients using nucleos(t)ide analogues (NUCs) or PEG-IFN. In the latest EASL HBV CPG, stopping NUC treatment after years of viral suppression and normalization of transaminases might be considered to boost immunological reactions in well characterized patients without advanced liver disease. The Pro’s and Con’s for that strategy will be discussed during the symposium.
Finally, long-term treatment and viral control with NUCS does not entirely prevent patients from progression of liver disease such as the development of HCC and may has some safety issues. Major advances in basic Hepatitis B research have paved the way for the identification of new therapeutic targets that are essential to obtain more functional cure of HBV in the future, i.e. HBsAg loss in patients with limited duration of therapies. The design of clinical trials with valid combination strategies using immunological approaches and novel direct antiviral compounds will be granted ample time at the symposium.


Introduction: Aims and open questions in HBV management
Jörg Petersen , Germany
14 April 2018 14:00 - 14:10

Fighting HBV with limited resources: The global perspective
Maud Lemoine , United Kingdom
14 April 2018 14:10 - 14:30

Stopping NUC therapy before HBsAg loss – a good idea?
Florian van Bömmel , Germany
14 April 2018 14:30 - 14:50

The road ahead – will novel HBV treatments enter clinics soon? Immunological therapies
Mala Maini , United Kingdom
14 April 2018 14:50 - 15:05

The road ahead – will novel HBV treatments enter clinics soon? Antiviral therapies
Man-Fung Yuen , Hong Kong
14 April 2018 15:05 - 15:20

14 April 2018 15:20 - 15:30